Spots Global Cancer Trial Database for relapsed or refractory acute myeloid leukemia
Every month we try and update this database with for relapsed or refractory acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | NCT03765541 | Relapsed or Ref... | Dexamethasone Amsacrine Cytarabine Azacitidine | 18 Years - | University Hospital, Toulouse | |
| NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT05247957 | Safety and Effi... | CAR-NK cells | 10 Years - 75 Years | Hangzhou Cheetah Cell Therapeutics Co., Ltd | |
| Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML | NCT04842370 | Relapsed or Ref... | PHI-101 | 18 Years - | Seoul National University Hospital | |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03850574 | Relapsed or Ref... | Tuspetinib Venetoclax Oral... | 18 Years - | Aptose Biosciences Inc. | |
| Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | NCT03765541 | Relapsed or Ref... | Dexamethasone Amsacrine Cytarabine Azacitidine | 18 Years - | University Hospital, Toulouse | |
| A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) | NCT05038800 | Relapsed or Ref... Relapsed or Ref... | MK-0482 | 18 Years - | Merck Sharp & Dohme LLC | |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03850574 | Relapsed or Ref... | Tuspetinib Venetoclax Oral... | 18 Years - | Aptose Biosciences Inc. | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML | NCT04842370 | Relapsed or Ref... | PHI-101 | 18 Years - | Seoul National University Hospital | |
| A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation | NCT04176393 | Relapsed or Ref... | ivosidenib | 18 Years - | CStone Pharmaceuticals | |
| A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | NCT01853228 | Acute Myeloid L... | Phase1 and Phas... Phase 1: cytara... Phase 2: cytara... | 1 Month - 18 Years | Janssen Research & Development, LLC | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia | NCT02675452 | Relapsed or Ref... Relapsed or Ref... | AMG 176 Azacitidine Itraconazole | 18 Years - 85 Years | Amgen | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML | NCT06385808 | Relapse Leukemi... Refractory Acut... Conditioning Hematopoietic S... | MTBF regimen | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes | NCT04951778 | Leukemia, Myelo... Myelodysplastic... | CC-91633 | 18 Years - | Celgene | |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | NCT05522192 | Relapsed or Ref... | Mitoxantrone li... Venetoclax | 18 Years - 75 Years | First Affiliated Hospital of Jinan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
